AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34346266 — intervention group
Group type: COMPARATOR
Intervention: SAL/FLU high-dose (50/500 μg)
Number of subjects: 323
Study 33759964 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted training
Number of subjects: 90
Study 33759964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 90
Study 33759964 — intervention group
Group type: COMPARATOR
Intervention: Standard printed educational material with verbal information (Control)
Number of subjects: 90
Study 33755779 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment and medical consultations for residents with Parkinson's disease
Number of subjects: 85
Study 33755779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing staff knowledge and training
Number of subjects: 85
Study 33755779 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of falls and hospital stays
Number of subjects: 85
Study 33755779 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson-specific assistive technologies
Number of subjects: 85
Study 33491438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fya antigen
Number of subjects: 143
Study 33491438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fyb antigen
Number of subjects: 143
Study 33491438 — intervention group
Group type: EXPERIMENTAL
Intervention: FY phenotypes
Number of subjects: 143
Study 36125835 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 28
Study 36125835 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 28
Study 35277011 — intervention group
Group type: EXPERIMENTAL
Intervention: RLX2™ containing alpha‐s1‐casein tryptic hydrolysate and L‐theanine
Number of subjects: 39
Study 35277011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 33278754 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed family member (IFM) present during awakening process in ICU
Number of subjects: 73
Study 33278754 — intervention group
Group type: COMPARATOR
Intervention: Routine care and treatment practices without family presence
Number of subjects: 73
Study 34780993 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual placebo (sham heat protective glove)
Number of subjects: 48
Study 34780993 — intervention group
Group type: COMPARATOR
Intervention: Physical placebo administered to the own, physical body
Number of subjects: 48
Study 33631102 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic 2 (MET‐2); initial daily treatment of 10 oral capsules for 2 days, then 3 capsules for 8 days; higher dose if recurrence: 20 capsules for 2 days, then 3 capsules for 8 days.
Number of subjects: 19
Study 33631102 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic 2 (MET‐2)
Number of subjects: 19
Study 34310715 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 62
Study 34310715 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap plus collagen matrix (CAF + CM)
Number of subjects: 62
Study 33098276 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 hrs per week of discrete trial teaching (DTT)
Number of subjects: 87
Study 33098276 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 hrs per week of discrete trial teaching (DTT)
Number of subjects: 87
Study 33098276 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 hrs per week of naturalistic developmental behavioral intervention (NDBI)
Number of subjects: 87
Study 33098276 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 hrs per week of naturalistic developmental behavioral intervention (NDBI)
Number of subjects: 87
Study 34102298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid
Number of subjects: 211
Study 34102298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 35779302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 μg/kg)
Number of subjects: 86
Study 33819335 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex abutment (Group CX)
Number of subjects: 28
Study 33819335 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave abutment (Group CV)
Number of subjects: 28
Study 34131804 — intervention group
Group type: EXPERIMENTAL
Intervention: APTw imaging and radiomic features
Number of subjects: 81
Study 34131804 — intervention group
Group type: EXPERIMENTAL
Intervention: APTw-derived radiomics algorithm
Number of subjects: 81
Study 34131804 — intervention group
Group type: COMPARATOR
Intervention: APTw measures
Number of subjects: 81
Study 36053504 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided procedure
Number of subjects: 1682
Study 36053504 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided procedure
Number of subjects: 1682
Study 36053504 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR and IVUS guidance
Number of subjects: 1682
Study 32147060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek seed (FS) supplementation (5 g FS powder, 3 times a day)
Number of subjects: 50
Study 32147060 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-diabetic drugs and nutritional consults)
Number of subjects: 50
Study 33347020 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (high and low doses)
Number of subjects: 66
Study 33347020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32113924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen delivered via portable concentrators
Number of subjects: 30
Study 32113924 — intervention group
Group type: COMPARATOR
Intervention: Sham control (air delivered via portable concentrators)
Number of subjects: 30
Study 36477234 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual self-pollination
Number of subjects: 16
Study 36477234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal open pollination
Number of subjects: 16
Study 36477234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal open pollination
Number of subjects: 16
Study 36477234 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual cross-pollination (red-fleshed pitaya pollen on white-fleshed pitaya stigma)
Number of subjects: 16
Study 36477234 — intervention group
Group type: COMPARATOR
Intervention: Natural pollination
Number of subjects: 16
Study 34836088 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intake of 1.3 g of polyphenol-rich cocoa powder
Number of subjects: 20
Study 34836088 — intervention group
Group type: COMPARATOR
Intervention: Daily consumption of 1.3 g of polyphenol-rich cocoa powder for 28 days
Number of subjects: 20
Study 34836088 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intake and sustained supplementation
Number of subjects: 20
Study 33125438 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements of confederates who belonged to the same social category as participants
Number of subjects: 965
Study 34217164 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term spinal cord electrical stimulation (stSCS)
Number of subjects: 160
Study 34217164 — intervention group
Group type: COMPARATOR
Intervention: Nerve block therapy (Control)
Number of subjects: 160
Study 35562713 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 80
Study 35562713 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 32116098 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment
Number of subjects: 130
Study 33218534 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied to facilitate erector spinae
Number of subjects: 16
Study 35860186 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive tarsal sinus approach
Number of subjects: 0
Study 35860186 — intervention group
Group type: COMPARATOR
Intervention: Lateral L-shaped incision approach (Control)
Number of subjects: 0
Study 34803872 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) plus standard medical therapy
Number of subjects: 80
Study 34803872 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 80
Study 36440639 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 10 days
Number of subjects: 50
Study 36440639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33369276 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection 40 IU subcutaneously twice weekly for 15 days
Number of subjects: 2
Study 33369276 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection 80 IU subcutaneously twice weekly for 15 days
Number of subjects: 2
Study 33369276 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection 80 IU subcutaneously 3 times weekly for 15 days
Number of subjects: 2
Study 33369276 — intervention group
Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 0.5 mg subcutaneously for 5 days
Number of subjects: 2
Study 33369276 — intervention group
Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 0.75 mg subcutaneously for 5 days
Number of subjects: 2
Study 33369276 — intervention group
Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 1 mg subcutaneously for 5 days
Number of subjects: 2
Study 33369276 — intervention group
Group type: COMPARATOR
Intervention: Synthetic ACTH1‐24 depot 1 mg intramuscularly for 5 days
Number of subjects: 2
Study 32716299 — intervention group
Group type: EXPERIMENTAL
Intervention: ReZone (mHealth intervention)
Number of subjects: 409
Study 32716299 — intervention group
Group type: COMPARATOR
Intervention: Management as usual (control)
Number of subjects: 409
Study 36354026 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 3033
Study 36354026 — intervention group
Group type: COMPARATOR
Intervention: Sham remote ischaemic conditioning
Number of subjects: 3033
Study 34048940 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 245
Study 34048940 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA, 30 min)
Number of subjects: 245
Study 34048940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 35102743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week cervicovestibular rehabilitation program combined with SLAE
Number of subjects: 60
Study 35102743 — intervention group
Group type: COMPARATOR
Intervention: 6-week SLAE program alone
Number of subjects: 60
Study 33414435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered orally 1 hour before exposure sessions
Number of subjects: 46
Study 33414435 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally 1 hour before exposure sessions
Number of subjects: 46
Study 32571614 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction and usual activity
Number of subjects: 111
Study 32571614 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 111
Study 32571614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet and exercise
Number of subjects: 111
Study 32571614 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 35704106 — intervention group
Group type: COMPARATOR
Intervention: Transurethral fulguration (TUF)
Number of subjects: 52
Study 35704106 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral fulguration plus hydrodistension (TUF+HD)
Number of subjects: 52
Study 32280055 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g/day of high‐amylose maize (RS2) for 12 weeks
Number of subjects: 59
Study 32280055 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric amount of rapidly digestible starch amylopectin (CTL) for 12 weeks
Number of subjects: 59
Study 32280055 — intervention group
Group type: EXPERIMENTAL
Intervention: RS2
Number of subjects: 59
Study 36684395 — intervention group
Group type: EXPERIMENTAL
Intervention: evriMED500® MERM device
Number of subjects: 109
Study 36684395 — intervention group
Group type: COMPARATOR
Intervention: Standard in-person DOT
Number of subjects: 109
Study 36684395 — intervention group
Group type: EXPERIMENTAL
Intervention: MERM device usability
Number of subjects: 109
Study 36684395 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction and adherence correlation
Number of subjects: 109
Study 32967430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 10
Study 35834792 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS-guided NGT insertion
Number of subjects: 120
Study 35834792 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (control)
Number of subjects: 120
Study 33517896 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled high molecular weight hyaluronan (HMW-HA)
Number of subjects: 41
Study 33517896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 36456969 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment combined with routine treatment
Number of subjects: 222
Study 36456969 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (medication and rehabilitation)
Number of subjects: 222
Study 33830956 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 1454
Study 33830956 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic SARS-CoV-2 infection
Number of subjects: 1454
Study 33830956 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection (asymptomatic and symptomatic)
Number of subjects: 1454
Study 34237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 187
Study 34237250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 34237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 187
Study 33218305 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Communication Training (FCT) via telehealth
Number of subjects: 57
Study 33218305 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 57
Study 35387675 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call reminders one week before the appointment
Number of subjects: 1311
Study 35387675 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1311
Study 32737923 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin (TI)
Number of subjects: 138
Study 32737923 — intervention group
Group type: COMPARATOR
Intervention: Insulin Lispro (LIS)
Number of subjects: 138
Study 32466912 — intervention group
Group type: EXPERIMENTAL
Intervention: kcal information
Number of subjects: 480
Study 32466912 — intervention group
Group type: EXPERIMENTAL
Intervention: PA information
Number of subjects: 480
Study 32466912 — intervention group
Group type: EXPERIMENTAL
Intervention: kcal + PA information
Number of subjects: 480
Study 32466912 — intervention group
Group type: COMPARATOR
Intervention: blind condition
Number of subjects: 480
Study 35863836 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose trimethoprim-sulfamethoxazole (10 mg/kg/day of TMP)
Number of subjects: 0
Study 35863836 — intervention group
Group type: COMPARATOR
Intervention: Standard of care trimethoprim-sulfamethoxazole (15 mg/kg/day of TMP)
Number of subjects: 0
Study 33800711 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic algorithm
Number of subjects: 0
Study 33800711 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage greedy randomized adaptive search (GRASP)
Number of subjects: 0
Study 33800711 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage stochastic sample greedy (SSD)
Number of subjects: 0
Study 33800711 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASP
Number of subjects: 0
Study 32902647 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) during radiotherapy
Number of subjects: 0
Study 32902647 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without androgen deprivation therapy (ADT)
Number of subjects: 0
Study 36050264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms based on clinical prognostic factors, IVIM‐DWI parameters, and MRI-derived radiomics
Number of subjects: 115
Study 33403890 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target <140/90 mmHg
Number of subjects: 15245
Study 33403890 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target <130/80 mmHg
Number of subjects: 15245
Study 33403890 — intervention group
Group type: COMPARATOR
Intervention: Overall cardiovascular outcomes
Number of subjects: 15245
Study 33403890 — intervention group
Group type: COMPARATOR
Intervention: Primary cardiac endpoint
Number of subjects: 15245
Study 32000822 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosgel®
Number of subjects: 430
Study 32000822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 35483733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1250
Study 35483733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study 33512755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg
Number of subjects: 184
Study 33512755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 33512755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin for 52 weeks
Number of subjects: 184
Study 33512755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin for 36 weeks (switched from placebo at Week 16)
Number of subjects: 184
Study 33512755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Number of subjects: 184
Study 35504446 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkoniumchloride (BAC) mouthrinse
Number of subjects: 0
Study 35504446 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 0
Study 32827113 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM muscle flap
Number of subjects: 15
Study 32827113 — intervention group
Group type: EXPERIMENTAL
Intervention: PBD muscle flap
Number of subjects: 15
Study 32827113 — intervention group
Group type: COMPARATOR
Intervention: No reconstruction (NR)
Number of subjects: 15
Study 33734030 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA)
Number of subjects: 66
Study 35810336 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (high‐intensity interval exercise at 80% of VO2max, with 1‐minute high‐intensity intervals at 95% of VO2max, twice a week for 3 months)
Number of subjects: 32
Study 35810336 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (high‐intensity interval exercise)
Number of subjects: 32
Study 35810336 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (no exercise)
Number of subjects: 32
Study 32361799 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-religious classes for 15 sessions
Number of subjects: 152
Study 32361799 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was provided)
Number of subjects: 152
Study 35429480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone (maximum dose 63 mg/kg per day for patients weighing ≤28 kg or 1800 mg/day for patients weighing >28 kg)
Number of subjects: 101
Study 35429480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 35429480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 101
Study 33998590 — intervention group
Group type: EXPERIMENTAL
Intervention: Job stress dimensions (Demand-Control-Social Support and Effort-Reward Imbalance models)
Number of subjects: 495
Study 33998590 — intervention group
Group type: EXPERIMENTAL
Intervention: High psychological demands, low decision latitude, low social support, high effort-reward ratio
Number of subjects: 495
Study 32800391 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 41
Study 32800391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Exercises (OE)
Number of subjects: 41
Study 32800391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 33445967 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing Hanks' disclosure post
Number of subjects: 682
Study 33445967 — intervention group
Group type: COMPARATOR
Intervention: Not seeing Hanks' disclosure post
Number of subjects: 682
Study 34022169 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter-ECG recording for up to 7 days in hospital (intervention group)
Number of subjects: 3465
Study 34022169 — intervention group
Group type: COMPARATOR
Intervention: Usual diagnostic procedures for atrial fibrillation detection (control group)
Number of subjects: 3465
Study 32700944 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom behavior management training program
Number of subjects: 1818
Study 35372439 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 280
Study 35372439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 280
Study 33768391 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile app program
Number of subjects: 110
Study 33768391 — intervention group
Group type: COMPARATOR
Intervention: supervised health program
Number of subjects: 110
Study 35258786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 26
Study 35258786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Number of subjects: 26
Study 36418565 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-supplement (250 mg/day)
Number of subjects: 116
Study 36418565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 36418565 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-supplement
Number of subjects: 116
Study 34157024 — intervention group
Group type: EXPERIMENTAL
Intervention: six weekly group-format stroke risk reduction self-management training sessions
Number of subjects: 246
Study 34157024 — intervention group
Group type: COMPARATOR
Intervention: enhanced treatment control (information on cardiovascular risk)
Number of subjects: 246
Study 32171028 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) during hospital stay
Number of subjects: 2637